20 Facts About Bicalutamide

Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer.

Bicalutamide is used to treat excessive hair growth and scalp hair loss in women, as a component of feminizing hormone therapy for transgender women, to treat early puberty in boys, and to prevent overly long-lasting erections in men.

Bicalutamide is a member of the nonsteroidal antiandrogen group of medications.

Bicalutamide is well-absorbed, and its absorption is not affected by food.

Bicalutamide was patented in 1982 and approved for medical use in 1995.

Related searches

Bicalutamide is approved for and mainly used in the following indications:.

Bicalutamide is pregnancy category X, or "contraindicated in pregnancy", in the U S, and pregnancy category D, the second most restricted rating, in Australia.

Bicalutamide has been associated with abnormal liver function tests such as elevated liver enzymes.

Bicalutamide has specifically been found to displace coumarin anticoagulants like warfarin from their plasma binding proteins in vitro, potentially resulting in an increased anticoagulant effect, and for this reason, close monitoring of prothrombin time and dosage adjustment as necessary is recommended when bicalutamide is used in combination with these drugs.

Bicalutamide monotherapy seems to have minimal effect on testicular spermatogenesis, testicular ultrastructure, and certain aspects of male fertility.

Bicalutamide is eliminated in similar proportions in feces and urine, while its metabolites are eliminated roughly equally in urine and bile.

Bicalutamide is a synthetic and nonsteroidal compound which was derived from flutamide.

Bicalutamide is a diarylpropionamide while flutamide is a monoarylpropionamide and nilutamide is a hydantoin.

Bicalutamide is a modification of flutamide in which a 4-fluorophenylsulfonyl moiety has been added and the nitro group on the original phenyl ring has been replaced with a cyano group.

Bicalutamide was first studied in a phase I clinical trial in 1987 and the results of the first phase II clinical trial in prostate cancer were published in 1990.

Bicalutamide was the fourth antiandrogen to be introduced for the treatment of prostate cancer, following the SAA CPA in 1973 and the NSAAs flutamide in 1983 and nilutamide in 1989 .

Bicalutamide is the generic name of the drug in English and French and its INN, USAN, USP, BAN, DCF, AAN, and JAN.

Bicalutamide is marketed by AstraZeneca in oral tablet form under the brand names Casodex, Cosudex, Calutide, Calumid, and Kalumid in many countries.

Bicalutamide has been studied in combination with the 5a-reductase inhibitors finasteride and dutasteride in prostate cancer.

Bicalutamide has been studied in a phase II clinical trial for ovarian cancer in women.